Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Sep;67(3):457-61.
doi: 10.1111/j.1365-2265.2007.02911.x. Epub 2007 Jun 7.

GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism

Affiliations

GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism

M Tauber et al. Clin Endocrinol (Oxf). 2007 Sep.

Abstract

Objective: The polymorphic deletion of exon 3 of the GH receptor (d3-GHR) has recently been linked to the magnitude of growth response to recombinant human GH (rhGH) therapy in short children with or without GH deficiency. We investigated this association in a large multinational cohort from the Network of European Studies of Genes in Growth (NESTEGG), comprising short children born small for gestational age (SGA).

Design: The study included short prepubertal SGA children treated with rhGH for 1 or 2 years.

Population: Two hundred and forty white Caucasian SGA children (138 male, 102 female) aged 6.6 +/- 2.3 years with a height at -3.0 +/- 0.7 SDS at start of rhGH treatment; 193 ethnically matched controls.

Methods: The GHR polymorphism (fl/fl, fl/d3 or d3/d3) was genotyped by polymerase chain reaction (PCR) multiplex assay. Growth velocity (G/V) in cm/year and changes in GV during the first and second year of rhGH treatment were evaluated.

Results: The change in GV was significantly greater in SGA children carrying one or two copies of the d3-GHR allele (P = 0.038 for the first year and P = 0.041 for the second year of GH treatment), but the change in height was not significantly different. Birthweight was significantly lower in SGA children with the d3/d3 genotype than in SGA children with the fl/fl genotype (P = 0.034) and in those with the fl/d3 genotype (P = 0.016).

Conclusion: Our data, based on a large cohort, showed that the exon 3 GHR polymorphism is associated with responsiveness to rhGH treatment in SGA children with short stature.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Change in growth velocity during the first year of GH treatment in the 240 SGA children according to the dose of rhGH: high dose 0·43 ± 0·17 mg/kg/week; low dose 0·21 ± 0·04 mg/kg/week. Results are presented as boxes with the horizontal line inside the box representing the mean and the vertical line representing the interquartile range (10th–90th centiles). The extreme values are presented as circles. The d3/d3 + fl/d3 group (or D group) is in white and the fl/fl group is in grey.
Fig. 2
Fig. 2
Studentized residuals in the three genotype groups are calculated according to the KIGS growth prediction model for SGA, incorporating rhGH dose, age and weight at start of therapy as well as gender-adjusted midparental height. Results are presented as boxes with the horizontal line inside the box representing the mean and the vertical line representing the interquartile range (10th–90th centiles). Positive studentized residuals indicate growth that exceeded the prediction, negative values growth below the prediction. The asterisk indicates a significant difference between the predicted growth velocity and the observed growth velocity (P = 0·04).

Similar articles

Cited by

References

    1. Bryant J, Cave C, Milne R. Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database of Systematic Reviews. 2003;4 CD00440. - PubMed
    1. Ranke MB, Lindberg A, Cowell CT, Wikland KA, Reiter EO, Wilton P, Price DA on behalf of the KIGS International Board. Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database) Journal of Clinical Endocrinology and Metabolism. 2003;88:125–131. - PubMed
    1. Rosenbloom AL. A mathematical model for predicting growth response to growth hormone replacement therapy – a useful clinical tool or an intellectual exercise? Journal of Clinical Endocrinology and Metabolism. 1999;84:1172–1173. - PubMed
    1. Pantel J, Machinis K, Sobrier ML, Duquesnoy P, Goossens M, Amselem S. Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. Journal of Biological Chemistry. 2000;275:18664–18669. - PubMed
    1. Sobrier ML, Duquesnoy P, Duriez B, Amselem S. Expression and binding properties of two isoforms of the human growth hormone receptor. FEBS Letters. 1993;319:16–20. - PubMed

MeSH terms